

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

***ESCHERICHIA COLI O157:H7 EPITHELIAL ADHESIN*****Field of the Invention**

The invention relates to genetic engineering and particularly to the demonstration that a contiguous segment of chromosomal DNA from *E. coli* O157:H7 encodes an adhesin that 5 mediates colonization of the gastrointestinal tracts of bovines, and possibly humans, with *E. coli* O157:H7 and bacteria using structurally related adherence mechanisms.

**Background of the Invention**

*E. coli* O157:H7 is a virulent and common foodborne pathogen. Most outbreaks, and many sporadic cases (38,42; see the appended Citations), have been attributed to food of 10 bovine origin. Most *E. coli* O157:H7 infections are sporadic, but this organism can cause massive epidemics by contamination of ground beef (19) and water (69). *E. coli* O157:H7 is transmissible from person to person, but the disappearance of the strain which caused the massive 1993 outbreak in Washington State soon after recall of the incriminated vehicle demonstrates that ingestion of contaminated beef, and not person to person spread, is the 15 chief source of human infection.

*E. coli* O157:H7 organism elaborates Shiga-like toxins (SLT) I and/or II. SLT I and II inhibit protein synthesis by disrupting a glycosidic bond at a specific adenine (A4324) in 28S rRNA of the 60S ribosomal subunit. SLT-producing *E. coli* (SLTEC) are ubiquitous in food (62) and animals (47). The vast majority are probably not human pathogens.

20 Current data suggest that *E. coli* O157:H7 is the most common and medically significant SLTEC. Only one outbreak of bloody diarrhea caused by SLTEC other than *E. coli* O157:H7 has ever been reported (11). Additionally, even when sought appropriately, non-O157:H7 SLTEC are rarely found in stools submitted for bacterial culture in North America compared to their frequency in the environment (8,52,59). Moreover, *E. coli*

O157:H7 is the predominant precipitant of the hemolytic uremic syndrome (HUS), the most important complication of enteric infection with *E. coli* O157:H7. For example, *E. coli* O157:H7 was found in 96% of HUS patients if stool was obtained within the first six days of diarrhea (72). Even though non-O157:H7 SLTEC have caused some cases of HUS in several 5 foreign series (10,11,12,35,40), these strains have never been reported to cause HUS in the United States. These data suggest that *E. coli* O157:H7 is the most important cattle-borne human pathogen threatening the food supply of this country today.

Cattle are the only reservoir of *E. coli* O157:H7 so far identified. Approximately 1 in 200 apparently healthy northwestern United States dairy and beef cattle carry *E. coli* O157:H7, and 8 to 16% of herds have at least one infected animal (25). Similar carriage rates have been detected nationwide (26). These are probably minimum carriage rates, because the technique used to culture *E. coli* O157:H7 is relatively insensitive.

A very low inoculum of *E. coli* O157:H7 can cause human disease. Person to person spread occurs rather easily in outbreaks and among sporadic cases (5,6,60). Microbiologic 15 analysis of the contaminated hamburger from the 1993 Western United States outbreak demonstrated that only approximately 200 *E. coli* O157:H7 were present in each of the contaminated patties (46). It is probable that the inadequate cooking that was applied reduced this concentration by at least one log, suggesting that very few *E. coli* O157:H7, perhaps in the range of 1-10 bacteria, can cause clinically apparent infection.

Data suggest that the incidence of diseases caused by *E. coli* O157:H7 has increased in the United States, independent of ascertainment bias by diagnosing physicians (44,70). Additionally, an increasing rate of antibiotic resistance in Washington State human isolates of 20 *E. coli* O157:H7 might portend an increased prevalence of this pathogen in animals administered antibiotics. For example, before 1988, none of 56 strains of *E. coli* O157:H7 were resistant to a wide variety of antibiotics tested, whereas after 1988, 7.4% of 176 strains 25 were resistant to the same combination of antimicrobials (streptomycin, sulfamethoxazole, and tetracycline). It is probable that the selective pressure for the acquisition of antibiotic resistance in *E. coli* O157:H7 occurred in farm animals. This emerging resistance is of considerable concern because such strains might achieve a selective advantage over other 30 coliform bacilli in cattle given antibiotics, thereby increasing the frequency with which food of bovine origin is contaminated with this pathogen.

Because of the ease with which *E. coli* O157:H7 can cause human disease, it is crucial to reduce this pathogen in, or eliminate it from, its ecological niche, namely the gastrointestinal tracts of healthy cattle.

The molecular mechanisms used by *E. coli* O157:H7 to adhere to epithelial cells and 35 colonize animals are poorly characterized. However, the adhesive properties of *E. coli* O157:H7 have been noted by several investigators. Most North American strains of *E. coli*

O157:H7 displayed D-mannose-resistant adherence patterns to HEp-2 or Henle 407 cells (57). Most strains adhere in the form of localized microcolonies, a phenotype strongly linked to diarrhea in epidemiological studies of enteropathogenic *E. coli* (EPEC) (13,16). A 60 MDa plasmid is present in all strains of *E. coli* O157:H7, and one group associated the expression 5 of sparse D-mannose-resistant adhesion to Henle 407 cells to the presence of this plasmid (34). Plasmid-cured *E. coli* O157:H7 expressed no fimbriae and were nonadherent, and a 60 MDa plasmid from *E. coli* O157:H7 conferred weak adherence to non-adherent *E. coli* C600. However, other investigators have shown that plasmid-less *E. coli* O157:H7 were fimbriated, whereas laboratory *E. coli* strains were not (79). Furthermore, plasmid-cured *E. coli* 10 O157:H7 adheres to epithelial cells as well or better than its parent (22,33). Only one of five adherent strains of *E. coli* O157:H7 studied by Sherman et al. (66) was fimbriated, but this fimbriated strain also agglutinated erythrocytes. The agglutination was sensitive to D-mannose, suggesting that this adherence was due to type I fimbriae. Taken together, these 15 data suggest that an identifiable fimbrial structure is not responsible for the adherence of most *E. coli* O157:H7 to Henle 407 cells.

Outer membranes of *E. coli* O157:H7 competitively inhibit adherence to HEp-2 cells, an inhibition which is not due to H7 flagellin or O157 lipopolysaccharide (65). Adherence of 20 *E. coli* O157:H7 to HEp-2 cells was reduced, but not abolished, by antibody to a 94 kDa outer membrane protein (64). Antibodies to enterotoxigenic *E. coli* colonization factor antigens I and II do not detect surface structures on *E. coli* O157:H7 (78). *E. coli* O157:H7 do not have sequences homologous to the EPEC adherence factor plasmid or to the diffuse adherence adhesin (71).

Some investigators have suggested that the epithelial cell adhesin of *E. coli* O157:H7 is encoded by its *eae* gene (17). *E. coli* O157:H7 *eae* is related to *inv*, which encodes 25 *Yersinia* invasin, which also functions as an adhesin, and EPEC *eae*, which encodes intimin. An *eae* deletion mutant of *E. coli* O157:H7 neither adhered to HEp-2 cells nor caused the attaching and effacing (AE) lesion in newborn pigs (17). When deletion mutants were complemented in *trans* by an intact *eae* gene, the strain could again cause the AE lesion, but still could not adhere *in vitro*. However, data from other groups suggest that the *eae* gene 30 product is not an adhesin for *E. coli* O157:H7. First, despite sequence homology to *inv* in its bacterial localization and transmembrane domains, the receptor binding domain of *E. coli* O157:H7 *eae* is quite dissimilar (4,82). Second, an *eae* insertional mutant in *E. coli* O157:H7 retained the ability to adhere to HEp-2 cells in a quantitative adherence assay (41). Third, an *eae* gene product does not confer adherence on nonadherent laboratory strains of *E. coli*. 35 (Jerse, A., et al., Proc. Natl. Acad. Sci. USA 87:7839-7843, 1990) Thus, a molecule other than the *eae* gene product in *E. coli* O157:H7 appears to be the primary adhesin of *E. coli* O157:H7 for bovine epithelial cells, enabling this human pathogen to colonize the bovine

gastrointestinal tract.

Bacterial adhesins, when used as immunogens, prevent disease or colonization of mucosal surfaces by bacteria in many animals (1,18,21,29,30,36,49,50,55,61, 68,81, which are hereby incorporated by reference). The reduction of *E. coli* O157:H7 at its bovine source would enhance the microbiologic safety of food derived from cattle, and lessen the environmental biohazard risk posed by the approximately 100,000 cattle detectably infected with *E. coli* O157:H7 at any one time in the United States. The availability of antibody for passive immunization would greatly mitigate the harm engendered by outbreaks of this infection.

10

#### Summary of the Invention

Transposon-mediated mutations of *E. coli* O157:H7 have been isolated that do not adhere to HeLa cells and that have lost the ability to colonize bovine intestines. A HeLa cell *in vitro* system has been established that provides a means of assaying variants of *E. coli* O157:H7 for their ability to colonize cattle. The gene into which the transposon inserted have been sequenced. In a separate approach, two overlapping 40 kb segments of chromosomal DNA from *E. coli* O157:H7 have been cloned that confer D-mannose resistant adherence to nonadherent strains of *E. coli*. The overlapping region has been cloned, and *E. coli* HB101 expressing this overlapping region on a plasmid (ATCC No. 69648) have acquired the ability to adhere to epithelial cells of both human (HeLa) and bovine (MDBK) origin. These findings demonstrate that a contiguous segment of chromosomal DNA from *E. coli* O157:H7 encodes an adhesin, and that this same adhesin mediates both bacterial adherence to HeLa cells.

The adhesin-encoding region of *pear* has been identified as the nucleotide sequence of SEQ ID NO:4. Also described are recombinant expression vectors containing the adhesin-coding region, as are bacterial cells which are transformed with the recombinant expression vector. The recombinant adhesin preferably has the amino acid sequence of SEQ ID NO:4. Also described are immunological binding partners that bind to the recombinant adhesin. Vaccine formulations of the invention contain the recombinant adhesin encoded by a nucleic acid molecule that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:4.

30

#### Brief Description of the Drawings

FIGURE 1 shows shedding rates of *E. coli* O157:H7 from calves inoculated with adherent strain 86-24 and non-adherent strain F4. Bars = SE.

FIGURE 2 is a map demonstrating overlap region between cloned regions of pSC(A-G6) and pSC(T-H12), and an adherence-conferring subclone region of the overlap, *pear*.

35

#### Detailed Description of the Preferred Embodiment

*Escherichia coli* O157:H7 causes severe and potentially fatal infections in humans,

especially children. This pathogen is harbored by apparently healthy cattle. The molecular mechanisms underlying the carriage of *E. coli* O157:H7 by cattle are not understood. The invention provides an isolated adhesin that enables *E. coli* O157:H7 to adhere to epithelial cells *in vitro* and to colonize cattle.

5 Transposon-based mutants of *E. coli* O157:H7 have been identified that have lost the ability to adhere to epithelial cells. These same mutants colonize calves poorly compared to parental *E. coli* O157:H7. This finding validates the use of the HeLa cell adherence assay. Additionally, a region of the *E. coli* O157:H7 chromosome has been cloned that expresses the adhesin. This chromosomal region has been designated the epithelial adherence region (ear).

10 Two complementary approaches were used to identify the gene encoding the adhesin that enables *E. coli* O157:H7 to colonize bovine intestines. The first approach identified a transposon mutant of *E. coli* O157:H7 that has lost the ability to adhere to HeLa cells and that also colonizes cattle poorly. For the second approach, a segment (*pear*) of chromosomal DNA from *E. coli* O157:H7 was cloned which, when expressed in derivatives of nonadherent  
15 *E. coli* K12, provides these strains with the ability to adhere to HeLa cells.

20 Our sequence analysis demonstrates that the candidate adhesin of *E. coli* O157:H7 is a homolog of the IrgA protein in *Vibrio cholerae* (Goldberg, M.B., et al., Proc. Natl. Acad. Sci. USA 88:1125-1129, 1991). This molecule is related to the TonB dependent family of outer membrane proteins in *E. coli* (Goldberg, M.B., et al., Molecular Microbiology 6(16):2407-2418, 1992). The DNA sequence analysis of the *irgA* homolog which is encoded by *pear*, and the homology to genes encoding IrgA and CIR, are described in the following Examples.

#### EXAMPLE 1

##### Identification of mutants that have lost the ability to adhere to HeLa cells.

25 A prototype adherent strain, *E. coli* O157:H7 substrain 86-24, was isolated in 1986 from a patient with hemorrhagic colitis whose illness was traced to ground beef the patient had consumed in a fast food restaurant (23). The transposon *TnphoA* was used to mutagenize substrain 86-24 according to the procedures in the appended citations 73 and 74, which are hereby incorporated by reference. *TnphoA*, a *Tn5* derivative, carries the alkaline phosphatase gene (*phoA*) and inserts in random locations throughout the *E. coli* genome but only in 1-3 sites per target cell. Hence, an in-frame integration of *phoA* of *TnphoA* into regions of genes encoding an extracellular domain of a protein will result in the expression of PhoA.

30 PhoA-expressing *TnphoA* mutants of *E. coli* O157:H7 were tested in the HeLa cell assay to find nonadherent mutants. This assay is described in detail in citation 8, which is hereby incorporated by reference. Bias was avoided by coding each organism, and the examining microscopist was blinded to which samples were controls and which were mutants.

EPEC strain B171 was used as the positive control for localized adherence in all experiments (58). Negative controls were nonadherent *E. coli* HB101 and/or NM554 (56). Besides the prototype adherent substrain of *E. coli* O157:H7, 6 other substrains tested adhered in a localized pattern to HeLa cells in the presence of D-mannose.

5 As previously reported by others (75), day to day variability in the degree of adherence of *E. coli* O157:H7 to HeLa cells was typically observed. However, three of 177 *PhoA*-expressing transconjugants screened for adherence to HeLa cells proved to be consistently nonadherent when tested in the coded assay (strains A5, F4, and N11). Strains A5, F4, and N11 retained all other phenotypic and genotypic characteristics of the parent 10 strain of *E. coli* O157:H7.

15 Southern blot analysis determined the locations of the transposon insertions in adherent and non-adherent *TnphoA* mutants. DNA from strains A5, F4, and N11 and from adherent mutants H8, P11, and P12 were digested with *Mlu*I, which does not cleave DNA within *TnphoA*. Resulting fragments were separated in an agarose gel, transferred to Nytran, and probed with a fragment from the Tn5 central region of *TnphoA*. Interestingly, the results indicated that there were two *TnphoA* insertions in the nonadherent mutants A5 and N11, and three in F4, in apparently identical *Mlu*I bands of 23 and 16 kb length. Single integrations of *TnphoA* are demonstrated in each of the three adherent transconjugants. *TnphoA* integrated in the chromosome of strains A5, F4, and N11, and not in plasmid DNA.

20

## EXAMPLE 2

### Animal testing.

25 The nonadherent strain F4 and wild type *E. coli* O157:H7 were tested for their ability to colonize conventional Holstein calves (< 1 week old). After an initial feed of colostrum, calves were placed in individual holding pens in an isolation facility, and reared on whole cow's milk with free-choice access to water, alfalfa hay, and a high protein grain mixture. It was demonstrated at the outset that the calves were not excreting *E. coli* O157:H7 by culturing their feces on sorbitol-MacConkey agar (SMA). Four animals received either 10<sup>8</sup> adherent *E. coli* O157:H7 86-24 NaR or 10<sup>9</sup> nonadherent mutant strain F4. In dual challenge experiments, each of four calves simultaneously received 10<sup>8</sup> adherent *E. coli* O157:H7 86-24 30 and 10<sup>9</sup> nonadherent *TnphoA* mutant F4. *E. coli* O157:H7 was a spontaneously nalidixic acid resistant mutant selected on agar plates containing nalidixic acid. *TnphoA* encodes kanamycin resistance.

35 The respective antibiotic resistances of these strains were exploited to identify *E. coli* O157:H7 in fecal samples by screening for shed challenge organisms on sorbitol MacConkey agar (SMA) containing nalidixic acid with or without kanamycin. Antibiotic resistant, sorbitol nonfermenting colonies were confirmed to be *E. coli* O157:H7 by their reactivity in the O157

latex particle agglutination test (Oxoid *E. coli* 0157 Test; Unipath Limited, Hampshire, England). The nonadherent strain was detectable for fewer days and at lower concentrations as shown in FIGURE 1, which summarizes the results of all challenges. The animals showed no ill effects which could be attributed to the *E. coli* O157:H7.

5 The shedding index (cfu/g of stool x number of days shed) was significantly greater for the adherent than for the non-adherent strain when analyzed by non-parametric rank sum analysis (p=0.028). Strain F4 grows as well as strain 86-24 NalR in fresh bovine stool and rumen contents, and in liquid broth, incubated aerobically overnight. These data suggest that 10 the abbreviated excretion of the *TnphoA* mutant by the challenged calves is not related to decreased viability of the mutant compared to the parent strain, even though it is difficult to simulate *in vitro* the exact conditions of the calf gastrointestinal tract. By demonstrating that calves retain the adherent strain more effectively than the nonadherent strain, these results validate the use of the HeLa cell *in vitro* adhesion assay for use in development of other reagents relevant to vaccine preparation.

15

### EXAMPLE 3

#### Expression of a recombinant adhesin using chromosomal DNA from *E. coli* O157:H7.

A segment of DNA has been derived from the chromosome of *E. coli* O157:H7 strain 86-24 NalR that renders nonadherent *E. coli* NM554 adherent. To clone this segment, 20 approximately 2000 *PhoA* expressing and nonexpressing *TnphoA* mutants of *E. coli* O157:H7 86-24 NalR were screened, and one transconjugant (20D2B) was found that no longer reacted in the O157 latex particle agglutination test. This sorbitol negative mutant produced SLT II, was H7 antigen positive and  $\beta$ -glucuronidase negative, and possessed the same API score as the parental strain. (API score refers to a product produced by Analytab, 25 Plainview, NY, which determines multiple bacterial growth characteristics. A score is given for each characteristic; taken in total, the score speciates bacteria. Within a species, there may be multiple scores.) However, 20D2B was highly adherent to HeLa cells. A partial *Sca*3a digest of genomic DNA of the hyperadherent strain 20D2B was ligated into plasmid Supercos (pSC) (20,77), packaged, and used to transduce nonadherent laboratory strain NM554. This 30 experiment yielded 2200 transductants with an average of 40 kb of DNA inserted into the *Bam*HI site of pSC.

The 2200 cosmid clones were screened for adherence to HeLa cells, and two adherent clones were identified and designated pSC(A-G6) and pSC(T-H12). *E. coli* NM554 containing pSC(A-G6) and pSC(T-H12) adhered to HeLa cells in a diffuse rather than 35 localized pattern although nascent clusters were sometimes seen. Southern blotting demonstrated that: (a) the A-G6 and T-H12 determinants overlap by approximately 15 kb; (b) these inserts are derived from *E. coli* O157:H7 chromosomal DNA; (c) the inserts do not

encode *eae*, *bfp* (which encodes the bundle forming pilus adhesin of EPEC), or SLT II; and (d) the overlap region is conserved in each of 9 *E. coli* O157:H7 tested, but not in *E. coli* HB101, DH5 $\alpha$ , or EPEC B171.

As shown in FIGURE 2, a deletion mutant of pSC(A-G6), designated "pSC(overlap)" (ATCC No. 69648), retains the overlapping segment between pSC(A-G6) and pSC(T-H12). Interestingly, nonadherent *E. coli* HB101 transformed with pSC(overlap) display diffuse adherence to Madin-Darby bovine kidney cells (MDBK), and, in a preliminary experiment, localized adherence to HeLa cells. An 8 kb subclone of pSC(overlap), designated "pear", restores adherence to non-adherent strain A5. (pear, and the *irgA* homologous subclone described below, display diffuse adherence to HeLa cells.)

The data summarized above suggest that: (1) an identifiable adhesin from *E. coli* O157:H7 expressed in *E. coli* HB101 (pear) enables *E. coli* O157:H7 to adhere to epithelial cells of human (HeLa) and bovine (MDBK) origin *in vitro*; and (2) this adhesin is the same molecule which permits *E. coli* O157:H7 to remain in the gastrointestinal tracts of bovines. Further identification and characterization of the subject recombinant *E. coli* O157:H7 adhesin is described below.

#### EXAMPLE 4

##### Identification of the genes on the adherence conferring plasmid (pear).

pSC(overlap) itself consists of 4 kb of pSC DNA and approximately 15 kb of *E. coli* O157:H7 DNA. pear consists of 8 kb of chromosomal DNA plus the SK $^+$  vector (Stratagene). To identify the adhesin expressed by pear, the entire fragment was sequenced and open reading frames were determined. The results are described below.

The appended SEQ ID NO:1 shows the 8,041 base pair nucleotide sequence of pear. Almost all of the sequence has been confirmed. Ambiguous DNA (in regions not encoding the candidate adhesin) is noted by N in the appended sequence. The pear insert contained three open reading frames (ORFs) of sufficient length to encode potential virulence or adherence factors. Two of these are homologous to genes necessary for resistance to tellurite (Jobling, MG, et al., Gene 66:245-258, 1988). These *terE* and *terD* homologs are shown in SEQ ID NO:2 and SEQ ID NO:3, corresponding respectively to nucleotides 7024-6449 and 7670-7092 of SEQ ID NO:1. The other ORF is homologous to a gene encoding a homolog of IrgA (Goldberg, MB, et al., Molecular Microbiology 6:2407-2418, 1992). This *irgA* homolog is shown in SEQ ID NO:4, which corresponds to nucleotides 3036-5126 of SEQ ID NO:1. IrgA is an outer membrane protein of *V. cholerae*, and is believed to be important for colonization of mice in an experimental system (Goldberg, MB, et al., Infection and Immunity, 58:55-60, 1990). The *E. coli* O157:H7 adhesin (SEQ ID NO:4) is also homologous to the *E. coli* colicin I receptor (CIR) (Griggs, D.W., et al., J. Bacteriol.

168:5343-5352, 1987). The amino acid homologies of the candidate adhesin to IrgA and to CIR are demonstrated by comparing SEQ ID NO:5 and SEQ ID NO:6, and SEQ ID NO:7 and SEQ ID NO:8, respectively.

#### EXAMPLE 5

5 Mutations in the *irgA* homolog, as cloned into an expression vector, lead to loss of adherence. Transposon (*TnphoA*) insertions in the *irgA* homolog of *E. coli* O157:H7 ablate adherence of laboratory strains of *E. coli* transformed with a plasmid vector into which an adherence conferring region has been inserted. We cannot state with certainty the exact site of the two *TnphoA* insertions which ablated adherence, but the regions of the insertions are  
10 between nucleotides 3271-3310 and 3801-3840 of SEQ ID NO:1.

#### EXAMPLE 6

A product of a single gene (i.e., the *irgA* homolog) confers adherence to nonadherent *E. coli*. We first performed PCR using as primers the sequences 5'GGGGATCCAATTCTGGCATGCCGAGGCAGTCG3' (SEQ ID NO:9), corresponding to  
15 nucleotides 2895-2914 of SEQ ID NO:1) and 3'GGACCGCCTTGTCAACGTTGCTCTTAGATCTGG5' (SEQ ID NO:10, corresponding to nucleotides 5176-5196 of SEQ ID NO:1) from which DNA on *pear* was amplified. These sequences were cloned into the *Bam*HI and *Xba*I sites of pSK+. We also amplified the same gene using as template DNA from *E. coli* O157:H7. In this latter case, the primers used were  
20 5'GGAAGGATCCCCAACACGCCATACGGATAGCTG3' (SEQ ID NO:11, corresponding to nucleotides 2867-2890 of SEQ ID NO:1) and 3'GCAACGGTGACGTTGAGGACCGCCAGATCTAAAGG5' (SEQ ID NO:12, corresponding to nucleotides 5159-5183 of SEQ ID NO:1). This latter PCR product was also cloned into pSK+, using the same *Bam*HI and *Xba*I sites. In both cases, multiple laboratory  
25 strains of nonadherent *E. coli* were rendered adherent to HeLa cells by these cloned single genes.

#### EXAMPLE 7

##### The adherence of $\Delta$ -*ear* mutants to HeLa cells is diminished.

Strain F12 of *E. coli* O157:H7 is a hyperadherent mutant that has been mutated by  
30 *TnphoA* such that the O157 antigen is no longer expressed (Bilge, S.S., et al., Abstract B-7, American Society of Microbiology, 21-25 May 1995). F12 is probably hyperadherent because the lack of expression of the O157 antigen enables the adhesin to be more completely exposed on the bacterial cell surface.

We deleted the entire 8041 base pair *Kpn*I-*Kpn*I region (SEQ ID NO:1) of *pear* from  
35 strain F12 as follows. We cloned *pear* into a suicide vector, pCVD442 (Donnenberg, MS, et al., Infection and Immunity, 59:4310-7, 1991), which was then mated into strain F12 using

*E. coli* SM10 lambda pir as a donor. Sucrose resistant, ampicillin sensitive strains were analyzed to find mutants with the SEQ ID NO:1 region deleted.

When the *ear* is deleted from strain F12, the organism was observed to be nonadherent or severely adherence deficient (1 cluster of microcolonies per 1-3 high powered fields) by an observer blinded to the identity of the F12 and the *ear* deletion mutant. (In comparison, the parent strain F12 displayed much higher levels of adherence to HeLa cells, approximately 0.5-1 cluster per cell.) This striking adherence deficiency could be complemented by the cloned genes of *irgA* from either the plasmid or the chromosome. Hence, this loss of adherence from the deletion of the *ear* is not caused by a polar effect of the deletion.

In summary, our data demonstrates that the PCR product of a single allele, an *irgA* homolog in *E. coli* O157:H7, confers an adherent phenotype when cloned into an appropriate vector and transformed into laboratory strains of *E. coli*. Tested strains include: *E. coli* NM554 (Raleigh, EA, et al, Nucleic Acids Research, 16:1563-75, 1988); *E. coli* HB101; and *E. coli* ORN172 (Woodall, LD, et al., Journal of Bacteriology 175: 2770-8, 1993), which is an *E. coli* K12 strain from which genes encoding type I pili have been deleted. Our deletion mutation data confirm that the epithelial adherence region (*ear*) encodes an *E. coli* O157:H7 adhesin. Sequence data suggest that this adhesin is a homolog of IrgA of *V. cholerae*.

We have also performed *TnphoA* mutagenesis of *E. coli* O157:H7, and identified three nonadherent mutants (strains A5, F4, and N11), each of which sustained a *TnphoA* insertion in the same allele (SEQ ID NO:9). One of these strains, strain F4, was deficient in its ability to colonize in calves in an oral challenge experiment performed at the Washington State University in Pullman, Washington. Sequence analysis suggests that the *TnphoA* insertion in the same allele among the three nonadherent mutants may have taken place in the midst of a cluster of genes, at least one of which has homology to pro-secretory proteins in *Yersinia enterocolitica* (YscJ) (Michiels, T., et al., Journal of Bacteriology 173:4994-5009, 1991), *Rhizobium fredii* (Nolt) (Meinhardt, L.W., et al., Molecular Microbiology 6:2407-2418, 1992), and *Xanthomonas campestris* (HrpB) (Fenselan, S., et al., Molecular Plant-Microbe Interactions 5:390-396, 1992), and it is possible that the secretion of the *E. coli* O157:H7 adhesin is controlled by this secretory mechanism.

30

#### EXAMPLE 8

##### Construct recombinants and deletion mutants for bovine challenge experiments.

Our data suggest that adherence to HeLa cells by *E. coli* O157:H7 correlates with optimal colonization of calves with this organism. However, the *E. coli* O157:H7 adhesin is not closely linked to a locus mutagenized by *TnphoA* in nonadherent strain F4. To exclude the possibility that separate *in vitro* and *in vivo* adherence mechanisms exist for *E. coli* O157:H7, we may (1) colonize calves with a laboratory *E. coli* expressing the recombinant

35

O157:H7 adhesin; (2) immunize animals with a recombinant adhesin and ascertain if these animals are protected from challenge with *E. coli* O157:H7; or (3) create an isogenic deletion mutant of *E. coli* O157:H7 and determine if this strain has lost its ability to adhere to HeLa cells and to colonize calves.

5

#### EXAMPLE 9

##### Study adhesin deletion mutants of *E. coli* O157:H7 in calves.

We shall determine if adhesin-deletion mutants of *E. coli* O157:H7 lose the ability to colonize challenged animals in the calf model. We have demonstrated that wild type *E. coli* O157:H7 colonizes the gastrointestinal tracts of calves longer and at higher concentrations than does a nonadherent *TnphoA* mutant. Ideally, we would challenge calves with a laboratory strain of *E. coli* expressing the recombinant adhesin of *ear*, and follow excretion of this organism. However, it is very unlikely that a recombinant host strain will survive in the gastrointestinal tract of animals. For example, plasmids of enterotoxigenic *E. coli* encoding K88 (F4) or K99 (F5) pilus adhesins did not confer the ability to colonize pig small intestine when transferred to laboratory *E. coli* strain K12, despite the clearly demonstrated role of these adhesins to colonizations of the small intestines in the wild type strains (48). Therefore, we use specific deletion mutants to authenticate the role of the *in vitro* adhesin in the calf model.

To validate the role of the *ear* adhesin in bovine colonization, we created an isogenic, in-frame deletion mutant of almost all of the *irgA* homolog in *E. coli* O157:H7. To do this, we cloned regions (ca. 0.45 kb) flanking the gene encoding the IrgA homolog adhesin, up to and including nucleotide 3110 at the 5' region, and nucleotide 5051 at the 3' region of the gene encoding the IrgA homolog adhesin, such that the 1941 nucleotides between nucleotides 3110 and 5051, inclusive, are deleted from this construct, corresponding to 647 amino acids. These truncated sequences of the IrgA homolog adhesin were then inserted into pCVD442, and deletion mutants of strain 86-24 NalR were identified by virtue of their ampicillin sensitivity and sucrose resistance. The deletion was confirmed in two mutants by Southern blotting using as probes the internal (i.e., deleted) portion of *irgA* homologs and DNA flanking the deleted sequences. The deletion mutant is termed 86-24 ( $\Delta$  *irgA*). The parent strain (86-24 NalR) and a ten-fold excess of deletion mutant 86-24 ( $\Delta$  *irgA*) will be fed simultaneously to cattle, and fecal excretion will be monitored by culturing stool on SMA plates containing nalidixic acid. A representative number of strains will be collected at multiple time points after challenge, until clearance of the challenge strains, or until 60 days post challenge, whichever comes first. These strains will be individually tested for the presence of the *irgA* deleted sequences using the polymerase chain reaction, to determine which of the strains colonizes the cattle.

In a representative experiment, animals are challenged with dual inocula (adherent and excess nonadherent deletion mutant of *E. coli* O157:H7). Based on previous challenges, we can anticipate that at least 6 calves will excrete *E. coli* O157:H7 for at least 21 days after inoculation.

5 Study the humoral and secretory immune response of the calves challenged with *E. coli* O157:H7: The immune response of bovines to enteric colonization with *E. coli* O157:H7 is unknown. The calf challenge experiments described above provide a model to study this response. In particular, the humoral and secretory immune response to various *E. coli* O157:H7 components, including but not limited to the recombinant adhesin, can be  
10 quantified to determine if the development of a response is correlated to the clearance of this organism from the gastrointestinal tract.

15 To study the immune response of the challenged bovines to *E. coli* O157:H7, serum and saliva are obtained from each calf prior to challenge and at each sampling time, and stored at -70°C. Intestinal secretions are saved at the end of the experiment, when animals are necropsied.

20 The humoral and secretory immune responses of the challenged bovines to *E. coli* O157:H7 proteins are studied by protein immunoblot. Outer membranes, as well as whole cell preparations, of *E. coli* O157:H7 86-24, *E. coli* NM554 pSC(A-G6), *E. coli* NM554 pSC(T-H12), and *E. coli* HB101 (parent or a derivative) are electrophoresed in adjacent lanes in 10% SDS-PAGE gels and transferred electrophoretically to nitrocellulose membranes (32). Outer membranes from nonadherent *E. coli* are included as controls. The membranes are probed with calf serum and intestinal secretions, and adherent primary antibodies are detected by murine monoclonal antibodies to bovine IgG1, IgG2, IgM, and IgA, and goat antimouse IgG coupled to horseradish peroxidase. In control blots, the monoclonal antibodies are replaced  
25 with isotype-matched monoclonal antibodies to irrelevant antigens.

30 Protein immunoblot studies are extended to the recombinant adhesin produced above using pGEX (67) as well as to other strains of *E. coli* O157:H7. Antibodies from calves challenged in this section are also used in an attempt to inhibit *in vitro* adherence of *E. coli* O157:H7 strain 86-24 and the recombinant adherent strains to epithelial cells. Finally, the recombinant adhesin is an appropriate target molecule for an enzyme-linked immunosorbent assay to quantify the magnitude of the antibody response to the adhesin in cattle challenged with *E. coli* O157:H7.

#### EXAMPLE 10

##### Immunological characterization of a recombinant *E. coli* O157:H7 adhesin.

35 Standard immunochemical techniques are used to determine if the cloned adhesin (SEQ ID NO:4) is the same as the adhesin used by *E. coli* O157:H7 to adhere to HeLa cells.

To achieve this objective, outer membrane proteins are prepared from laboratory strain(s) expressing the recombinant adhesin (SEQ ID NO:4). These proteins are analyzed on SDS-polyacrylamide gels, and used to immunize rabbits at three one-month intervals and Holstein cows at 30 and 60 days prepartum. Rabbits are also be immunized with killed whole bacterial cell preparations. A recombinant *E. coli* NM554, which does not adhere to HeLa cells, is used as a negative control immunogen.

Decomplemented serum from immunized rabbits and cows, and whey from the milk of immunized cows, is first absorbed against *E. coli* NM554 to deplete antibodies to outer membrane proteins which are irrelevant to adherence. The absorbed sera and milk are tested against *E. coli* O157:H7 strain 86-24, as well as additional strains, using immunofluorescence and Western blotting to determine if antibody to the recombinant antigen has specific affinity for extracellular antigens or outer membrane proteins, and to determine if this antigen is conserved. Negative control antigens consist of other *E. coli*, including diarrheagenic strains, as well as other Shiga like toxin-producing *E. coli* which do not belong to serotype O157:H7. 15 Additional negative antibody controls include preimmune serum, and serum and milk obtained from animals immunized with nonadherent recombinant *E. coli* NM554.

The function of anti-adhesin antibodies is assessed using the *in vitro* HeLa cell assay, adapted to quantify the numbers of bacteria adherent to the target cells. *E. coli* O157:H7, as well as adherent and nonadherent recombinant *E. coli* NM554, are incubated with immune or 20 control sera or milk antibodies before addition to the HeLa cell culture. Antibodies remain in the adherence assay medium. Additionally used in these assays are antibodies in serum and saliva from animals challenged with oral *E. coli* O157:H7. After the appropriate incubation period, the number of bacteria adherent per cell is enumerated in multiple fields consisting of several hundred eukaryotic cells. The microscopist is blinded to the identity of the strains and 25 antibodies.

The anti-adhesin antibodies raised and selected as described above are also useful for the diagnostic identification of *E. coli* O157:H7. So too are *E. coli* O157:H7 nucleotide sequences within or flanking the *irgA* homolog having the requisite specificity and sensitivity for diagnosing the presence of strain O157:H7 in feed animals, food, and humans, as 30 determined by screening a panel of closely related bacterial strains for specificity, and a panel of *E. coli* O157:H7 for sensitivity.

#### EXAMPLE 11

##### Immunoprophylactic vaccines.

Bacterial adhesins have been used as immunogens to prevent colonization of mucosal 35 surfaces and/or disease in multiple food and laboratory animals. An immunoprophylactic approach to the problem of *E. coli* O157:H7 carriage using a purified recombinant adhesin

(*ear* or subclone thereof) as a vaccine is considered to be an efficient method to improve the microbiologic safety of food of bovine origin. Preparation and administration protocols for such vaccines are known in the art. See, e.g., U.S. Patents No. 5,286,484; No. 5,208,024; No. 5,137,721; No. 5,079,165; No. 5,066,596; No. 4,795,803; No. 4,736,017; 5 No. 4,702,911; No. 4,725,435; No. 4,454,116; and No. 3,975,517, which are incorporated by reference herein.

It is well known in the art that vaccines administered to cattle can confer immunity to bacteria that colonize the gut. For example, U.S. No 3,975,517, describes operable methods for vaccinating cattle. Other published methods suitable for immunizing animals include: 10 Acres et al., 25 *Infection and Immunity* 121, 1979; Linggood et al., U.S. 4,971,794, 1990; Sadowski and Prairie, U.S. No. 4,652,448, 1987; Suchaux et al., 69 *Infection and Immunity* 2828, 1992; Francis and Willgoths, 52 *Am. J. Vet. Res* 1051, 1991; Ikemori et al., 53 *Am. J. Vet. Res.* 2005, 1992; Isaacson et al., 29 *Infection and Immunity* 824, 1980; Morgan et al., 22 *Infection and Immunity* 771, 1978; Morris et al., 13 *J. Med. Microbiol.* 265, 1980; 15 Runnels et al., 55 *Infection and Immunity* 555, 1987; Sojka et al., 11 *J. Med. Microbiol.* 493, 1978; and Yokoyama et al., 60 *Infection and Immunity* 998, 1992. Vaccines can be prepared and administered by a variety of routes, many of which are found in Harlow and Lane, *Antibodies*, 1988, which is hereby incorporated by reference.

20 Immunization with the *ear*-encoded *IrgA* homolog adhesin to result in decreased excretion of *E. coli* O157H7 requires generation of immune responses with effectors in the 25 gastrointestinal tract of adult and sub-adult cattle, the age groups which are presented for slaughter. In this age group, the presence of a functional rumen presents a major barrier to oral vaccination in a form designed to survive passage through the abomasum (the 'true' stomach), as the very large and metabolically active ruminal compartment is thought to block passage of most intact antigens to the abomasum.

Several strategies can result in immune responses in the intestine in adult ruminants. These include: the intramammary route mentioned below; parenteral (intramuscular) 30 immunization, because the resulting antibodies are cleared from circulation into the intestine; intranasal immunization (as antigen presentation by the pharyngeal tonsils is quite effective); and the use of highly stimulating adjuvants such as ISCOMs (immune stimulating complexes such as liposome-antigen combinations) or cholera toxin b-subunit conjugates.

Types Of Vaccines: Purified antigen (prepared using standard recombinant DNA methods) or whole-cell vaccines can be used to stimulate an immune response in pregnant cows, resulting in the presence of protective antibodies in the colostrum and milk produced 35 after parturition. The milk or colostrum can be stored for later administration to newborn calves. Alternatively, protein produced from the *irgA* homolog can be used to raise monoclonal antibodies which then can be used directly to confer passive immunity to newborn

calves. Methods for preparing monoclonal antibodies are well-known in the art, and can be found, for example, in Harlow and Lane, *Antibodies*, Cold Spring Harbor Laboratory, 1988.

Vaccines Containing Purified Antigen: Purified IgA homolog adhesin is formulated in sesame or peanut oil, sterile aqueous solution, or other isotonic solution suitable for injection.

5 Stabilizers such as sorbitol or gelatin may be added. The immunogenicity can be enhanced by including various immunoadjuvants in the pharmaceutical preparation. Immunoadjuvants useful for this purpose include the water-in-oil emulsion of Freund, light mineral oil (Bayol), the commercially available emulsifiers Arlacel A and Aracel C, or monophosphoryl lipid A.

10 Cows are inoculated subcutaneously above the left shoulder twice, approximately 3 and 6 weeks before the onset of calving.

15 Whole Cell Vaccines: A bacterial strain suitable for use as a whole-cell vaccine is a nonpathogenic (to animals and humans) bacterium expressing the homolog adhesin (SEQ ID NO:4). This strain can be administered orally as a live vaccine, or can be used as a killed vaccine. Oral vaccination is an efficient means for stimulating production of secretory IgA in mucosal tissues such as the internal lining of the intestinal tract. Using a killed vaccine is the safest choice, as it obviates the risk that the non-pathogenic vaccine strain will acquire virulence genes by genetic transfer from other bacteria that may be present in the gut.

20 Where the goal is to acquire materials suitable for providing passive immunization, another advantageous route of administration is to inject the vaccine preparation directly into the teat canal of pregnant or nursing cows. Whether administration is oral or via injection, the vaccinated animal will produce protective antibodies in her milk that will passively immunize recipient calves.

25 Preparation Of Formalin-Treated Vaccine: One means of vaccine preparation incorporates some of the advantages of both live and killed whole-cell vaccines. For this procedure, a bacterial strain expressing the antigenic protein is subjected to a controlled formalin treatment. A broth culture of the vaccine strain is grown to a concentration of about  $10^8$  to  $10^9$ , then incubated under aerobic conditions for 10 to 15 hours in the presence of about 0.04% (vol/vol) formalin (0.016% wt/vol formaldehyde). Alternatively, the vaccine strain is grown on solid media, and the cells scraped off and suspended in broth medium for 30 the formalin treatment. Formalin-treated bacteria remain viable, but optimally the proportion of colony-forming units is reduced by about 1000-fold compared with bacteria not exposed to formalin. For each batch of vaccine, plate counts are performed to ensure that the requisite proportion of bacteria have survived the formalin treatment. If necessary, the time of exposure to formalin and the percentage of formalin added to the broth are adjusted so that 35 the plate counts of post-treatment cultures are 1000-fold reduced compared with controls. The vaccine contains the entire broth culture constituents including metabolic waste products and extracellular proteins.

Virulence of vaccine strains are tested by oral inoculation of 3 to 4 day old suckling mice with either virulent *E. coli* O157:H7 or the formalin-treated vaccine strain. Each mouse is administered about  $10^6$  to  $10^8$  organisms in about 0.15 ml. Mice are orally inoculated with serial dilutions of the bacteria, and survival is determined at 40 hours.

5        Administration Of Vaccine: For oral administration, the formalin-treated vaccine strain is packaged in enteric coated capsules that dissolve only after passing through the stomach. To achieve prophylaxis with monoclonal antibodies, the antibody can be mixed with colostrum, or any pharmaceutical carrier suitable for oral administration.

10      Injection: Four to eight ml doses of the vaccine are administered intramuscularly or directly into the lactiferous ducts via the teat canals of two year old cows. For lactiferous duct administration, the cows are given a series of 4 to 6 ml doses at 42, 32, 22 and 12 days prior to parturition. For intramuscular vaccination, 4 ml of the formalinized culture is injected in the side of the neck 28 days before parturition, followed by 6 ml 14 days later, and 8 ml at 5 days before the expected calving day. About 1 liter of milk is collected from vaccinated and 15 control cows seven days after parturition. Whey is prepared by centrifuging milk for 44,000 g for two hours, then collecting the supernatant. Whey is stored either in 2 ml aliquots at 4°C, stored frozen at -30°C, or stored lyophilized.

20      To monitor antibody production in response to the vaccine, 1 l of milk is taken from vaccinated pregnant cows on 2,3,4,7 and 14 days after calving. Whey is prepared from the milk by centrifugation and stored as described above.

25      Challenging Passively-Immunized Calves: To demonstrate the protective effects of whey from vaccinated teats, newborn calves separated from their mothers are fed one aliquot of post-immune whey every 8 hours for 72 hours. Control calves are fed whey from non-vaccinated cows. Six hours after being fed the first dose of whey, the calves are infected orally with broth culture containing about  $10^9$ - $10^{10}$  colony forming units virulent *E. coli* O157:H7 per ml. Each day after being exposed to the O157:H7, stool samples from infected calves are cultured to detect the presence or absence of *E. coli* O157:H7. Three calves from each group are sacrificed after 10 days, and their intestines examined for the presence or absence of *E. coli* O157:H7.

30      Mucosal Immunization: An additional route of vaccination exploits the mucosal immune system, which provides a defense against colonization of surfaces lining the gastrointestinal and respiratory systems, and relies on the induction of IgA antibodies secreted from these organs into the lumens where organisms colonize, and viable bacterial vectors which are in themselves not harmful to animals or humans, but which could be genetically engineered to express the *E. coli* O157:H7 adhesin. For a review of mucosal immunization, see: McGhee, J.R., et al., Seminars in Hematology 30 (4 suppl 4):3-12, discussion 13-15,

1993. For example, an attenuated or harmless commensal organism, including but not limited to a member of the *Enterobacteriaceae*, is transformed with the *E. coli* O157:H7 recombinant adhesin. This construct is administered to animals orally, or via intranasal inoculation. The efficacy of this approach is measured by assaying for specific IgA to the antigen, or by challenging vaccinated and control animals with *E. coli* O157:H7, and following excretion of this pathogen.

10 Immunization With Recombinant Bacterial Antigen Produced in Transgenic Plants: An alternative approach to the prevention of the carriage of *E. coli* O157:H7 by food animals, and possibly by humans, is to introduce the *E. coli* O157:H7 adhesin expressed in transgenic plants. For example, Haq et al. introduced sequences encoding *E. coli* heat-labile enterotoxin (LT-B) on an expression vector into *Agrobacterium tumifaciens*. This host bacterial strain was used to transfer the sequences encoding LT-B into tobacco (*Nicotiana tabacum* cv. Samsun) and potato (*Solanum tuberosum* variety "Frito-Lay 1607") plants, which then expressed variable amounts of these toxin antigens, as determined by immunoassay. These 15 bacterial proteins were fed to mice, either in the form of extract of tobacco plants which expressed LT-B, or as potatoes expressing LT-B (i.e., no extract). In both cases, serum IgG and mucosal IgA responses to LT-B were elicited.

Thus, as an analogous approach in the immunization of cattle to prevent carriage of *E. coli* O157:H7, transgenic plants expressing the *E. coli* O157:H7 adhesin are fed to food animals. The response to the antigen is measured by assaying for circulating IgG and mucosal IgA antibodies specific for the *E. coli* O157:H7 adhesin. These animals could then be challenged with *E. coli* O157:H7, and excretion followed, with appropriate control animals also challenged, to determine if an immunoprotective response has been elicited. The determination of immunoprotection would be analogous to the challenge with the *irgA* homolog deletion mutants, but in this case, animals immunized with transgenic plants expressing the IrgA homolog adhesin, or a control (i.e., irrelevant) antigen will be challenged with nalidixic acid resistant *E. coli* O157:H7. The excretion of challenge organisms will be followed by plating stool on SMA with nalidixic acid, and the duration and level of shedding of *E. coli* O157:H7 in the two groups will be compared.

30 It is also contemplated that immunizing transgenic plants may be used to protect humans from infection with *E. coli* O157:H7 and related pathogens expressing the *E. coli* O157:H7 adhesin, or homologs of this adhesin. In the case of humans, IgA and IgG can be assayed to detect a humoral response to this protein, but challenge experiments cannot be performed because of the exceptional pathogenicity of *E. coli* O157:H7.

35 Use of a Recombinant Adhesin as a Competitive Inhibitor of *E. coli* O157:H7 in the Gastrointestinal Tracts of Food Animals and of Humans: Large quantities of recombinant adhesin expressed by plants and consumed in the diets of animals and humans may compete

with wild type *E. coli* O157:H7 and related pathogenic bacteria for binding sites on the enterocyte surface. For example, animals are put on such feed in the several days or weeks prior to shipment for slaughter, provided controlled challenge experiments show that the recombinant adhesin, expressed in plants which are then fed to the animals, promotes 5 clearance of *E. coli* O157:H7 from the gastrointestinal tract of such animals, thereby reducing the load of this pathogen that enters the production line in abattoirs. In a similar approach, children with the early stage of gastrointestinal infection with *E. coli* O157:H7 are administered these recombinant competitive inhibitors, including but not limited to the recombinant adhesin expressed on plants, to promote clearance of the organism, thereby 10 ameliorating infection, or preventing the development of hemolytic uremic syndrome (HUS). Also, contacts of children with *E. coli* O157:H7 infection, who have yet to display symptoms, are fed recombinant adhesin, with the intent that colonization in such potential secondary cases is prevented.

The disclosed adhesin may also be used to prevent or ameliorate human infection with 15 *E. coli* O157:H7, as well as with bacteria which use a homolog of this adhesin, with shared active sites or epitopes. As discussed above, the *E. coli* O157:H7 adhesin demonstrates striking homology to IrgA. There are domains of high degree of homology (conserved regions) interspersed with relatively nonconserved regions (variable regions). The possibility exists, therefore, that the IrgA homolog in *E. coli* O157:H7 can be used as an immunogen 20 (vaccine) against *V. cholerae* infections. An additional possibility is that the IrgA homolog in *E. coli* O157:H7 may be a useful vaccine against the carriage of other pathogenic *Enterobacteriaceae* by food animals, such as diarrheagenic *E. coli* that do not belong to serogroup O157:H7.

The IrgA homologue might also be useful in the induction of protective immunity, or 25 as a competitive inhibitor of colonization, in several additional hosts and in several additional infections. These include (1) a vaccine to prevent infections in humans caused by *E. coli* O157:H7, other diarrheagenic *E. coli*, and *V. cholerae*; (2) a vaccine to prevent carriage by cattle, and other animals destined for human food, of diarrheagenic *E. coli*; (3) a competitive inhibitor of colonizing diarrheagenic *E. coli* in food animals. To test the efficacy of these 30 approaches, multiple experiments are contemplated. These include (1) the administration of immune globulin (passive immunity) from donors immunized with the IrgA homolog adhesin to high risk patients (i.e., children in contact with a primary case of *E. coli* O157:H7 infection), in a placebo-controlled fashion, to determine the differences in attack rates between the two groups; (2) a vaccine formulation could be administered to human volunteers 35 subsequently challenged with *V. cholerae*, or to patients residing in areas of high risk for infection; (3) challenge of immunized food animals with related diarrheagenic *E. coli* (i.e., not *E. coli* O157:H7) and determine if colonization can be established. The possibility also exists

that animals infected with pathogenic *E. coli* sharing an IrgA-mediated adherence mechanism cause illness in the animal industry. The IrgA homolog adhesin may, in these cases, be used to diagnose, prevent, or treat the infection. In fact, we have identified *pear* sequences in RDEC-1 and some *E. coli* strains from calves with diarrhea.

5

### Glossary

Glossary of abbreviations, strains, plasmids, and genes relevant to this disclosure:

	EPEC	enteropathogenic <i>E. coli</i>
	MDBK	Madin-Darby bovine kidney cells
10	PhoA	alkaline phosphatase
	PBS	phosphate-buffered saline
	pSC	plasmid Supercos
	PCR	polymerase chain reaction
	SLT	Shiga-like toxins
15	SLT I	Shiga-like toxin I
	SLT II	Shiga-like toxin II
	SMA	sorbitol-MacConkey agar
	XP	5-bromo-4-chloro-3-indolylphosphate

20 *E. coli* O157:H7 86-24: An SLT-II producing isolate which caused a large restaurant-associated outbreak of hemorrhagic colitis which included two deaths (23,71).

*E. coli* O157:H7 NalR: Nalidixic acid resistant adherent mutant of *E. coli* O157:H7 86-24 used in *TnphoA* mutagenesis. This strain adheres in a localized pattern to HeLa cells.

25 *E. coli* O157:H7 Strains A5, F4, N11: *TnphoA* mutants of *E. coli* O157:H7 86-24 NalR which express PhoA, and are non-adherent, kanamycin resistant, and ampicillin sensitive.

*E. coli* O157:H7 Strains H8, P11, P12: *TnphoA* mutants of *E. coli* O157:H7 86-24 NalR which are adherent, kanamycin resistant, and ampicillin sensitive.

30 *E. coli* 20D2B: a *TnphoA* mutant of *E. coli* O157:H7 NalR which is hyperadherent. This strain does not express the O157 antigen, but retains all other characteristics of the parent strain (H7 antigen positive, sorbitol nonfermenting, SLT II positive, same API score).

*E. coli* NM554: A laboratory strain of *E. coli* used for cosmid cloning.

Plasmids used:

35 pSC(A-G6) and pSC(T-H12): overlapping cosmid clones containing 30 kb of *E. coli* O157:H7 chromosomal DNA expressed in *E. coli* NM554 which confers D-mannose-resistant

adherence on this *E. coli* in a mostly diffuse pattern.

pSC(overlap): deletion mutant of pSC(A-G6) which retains 15 kb overlap region, and confers adherence to *E. coli* HB101. pSC(overlap) was deposited on June 24, 1994, under accession number 69648 at the American Type Culture Collection, 12301 Parklawn Drive, 5 Rockville, MD 20852, U.S.A.

pGEX: A vector which allows the expression of the IrgA homolog adhesin and a molecule which can act as a ligand for an affinity purification step (67).

pear: adherence-conferring 7 kb subclone of pSC(overlap).

10 irgA: Iron regulated gene A, from *V. cholerae*. This has regions of homology to the adhesin of *E. coli* O157:H7 that was cloned and is described in this application.

CIR: *E. coli* colicin I receptor. *E. coli* outer membrane protein which also has regions of considerable homology to the described *E. coli* O157:H7 adhesin.

15 Strain F12: another O157 *TnphoA* mutant which has lost the ability to express the O157 antigen by virtue of having sustained a *TnphoA* insertion in the *rfb* locus. This strain is hyperadherent. ear deletions from F12 are considerably less adherent than the parent strain.

Strain 86-24 NalR ( $\Delta$  irgA): a deletion mutant of *E. coli* O157:H7 strain 86-24 NalR, which is used in calf challenge experiments.

20 ear (epithelial adherence region): subclone of 15 kb pSC(overlap) region between pSC(A-G6) and pSC(T-H12), representing approximately 7 kb of cloned *E. coli* O157:H7 chromosomal DNA which confers the adherence phenotype to nonadherent laboratory *E. coli*.

#### Citations

1. Acres, S.D., et al., *Infect Immun* 1979; 25:121-126.
2. Baga, M., et al., *Escherichia coli*. *EMBO J* 1985; 4:3887-3893.
3. Bakker, D., et al., *Escherichia coli*. *Mol Microbiol* 1991; 5:875-886.
- 25 4. Beebakhee, G., et al., *FEMS Microbiol Lett* 1992; 91:63-68.
5. Bell, B, personal communication.
6. Belongia, E.A., et al., *JAMA* 1993; 269:883-888.
7. Bilge, S.S., et al., *J Bacteriol* 1989; 171:4281-4289.
8. Bokete, T.N., et al., *Gastroenterology* 1993; 105:1724-1731.
- 30 9. Borczyk, A.A., et al., *Lancet* 1987; 1:98.
10. Caprioli, A, et al., *J Infect Dis* 1992; 166:154-158.
11. Caprioli, A, et al., *J Infect Dis* 1994; 169:208-211.
12. Cordovez A., et al., *J Clin Microbiol* 1992; 30:2153-2157.
13. Cravioto, A, et al., *Lancet* 1991; 337:262-264.
- 35 14. Donnenberg, M.S., et al., *Infect Immun* 1990; 58:1565-1571.
15. Donnenberg, M.S., et al., *Infect Immun* 1991; 59:4310-4317.
16. Donnenberg, M.S., et al., *Infect Immun* 1992; 60:3953-3961.

17. Donnenberg, M.S., et al., *J Clin Invest* 1993; 92:1418-1424.
18. Duchet-Suchaux, M., et al., *Infect Immun* 1992; 60:2828-2834.
19. Enteric Diseases Branch, CDC, *Morbid Mortal Wkly Rep* 1993; 42:85-86.
20. Evans, G.A., K. et al., *Gene* 1989; 79:9-20.
- 5 21. Francis, D.H., et al., *Am J Vet Res* 1991; 52:1051-1055.
22. Fratamico, PM, et al., *J Med Microbiol* 39:371-381, 1993.
23. Griffin, P.M., et al., *Ann Intern Med* 1988; 109:705-712.
24. Griffin, P.M., et al., *Epidemiol Rev* 1991; 13:60-98.
25. Hancock, D.D., et al., *Epidemiology and Infection* 113:119-207, 1994.
- 10 26. Hancock, D.D., et al., National Prevalence Study for *Escherichia coli* O157:H7 in United States Dairy Calves. Submitted.
27. Hancock, R.E.W., et al., *J Bacteriol* 1978; 136:381-90.
28. Henikoff, S., *Gene* 1984; 28:351-359.
29. Ikemori, Y., et al., *Am J Vet Res* 1992; 53:2005-2008.
- 15 30. Isaacson, R.E., et al., *Infect Immun* 1980; 29:824-826.
31. Jacobs, A.A.C., et al., *J Bacteriol* 1987; 169:735-741.
32. Johnstone, A., et al., *Immunochemistry in Practice*, 2nd Ed. Blackwell Scientific Publications, Oxford, 1987, pp 190-196.
33. Junkins, A., et al. *Curr Microbiol* 1989; 19:21-27.
- 20 34. Karch, H., et al., *Infect Immun* 1987; 55:455-461.
35. Karmali M.A., et al., *J Infect Dis* 1985; 151:775-782.
36. Kimura, A., et al., *Infect Immun* 1990; 58:7-16.
37. Krogfelt, K.A., *Rev Infect Dis* 1991; 13:721-735.
38. LeSaux, N., et al., *J Infect Dis* 1993; 176:500-502.
- 25 39. Lindberg, F., et al., *Nature* 1987; 325:84-87.
40. Lopez E.L., et al., *J Infect Dis* 1989; 160:469-475.
41. Louie, M., et al., *Infect Immun* 61:4085-4092, 1993.
42. MacDonald K.L., et al., *JAMA* 1988; 259:3567-3570.
43. Marshall, B., et al., *Proc Natl Acad Sci USA* 1990; 87:6009-6613.
- 30 44. Martin, D.L., et al., *N Engl J Med* 1990; 323:1161-1167.
45. Martin, M.L., et al., *Lancet* 1986; ii:1043.
46. McNamara, A.M., personal communication.
47. Montenegro, M.A., et al., *J Clin Microbiol* 1990; 28:1417-1421.
48. Moon, H.W., et al., *Am J Clin Nutrition* 1979; 32:119-127.
- 35 49. Morgan, R.L., et al., *Infect Immun* 1978; 22:771-777.
50. Morris, J.A., et al., *J Med Microbiol* 1980; 13:265-271.
51. Oudega, B., et al., *Antonie van Leeuwenhoek* 1988; 54:285-299.

52. Pai C.H., et al., *J Infect Dis* 1988; 157:1054-1057.
53. Pai, C.H., et al., *Infect Immun* 1986; 51:16-23.
54. Pararuchuri, D.K., et al., *Proc Natl Acad Sci USA* 1990; 87:333-337.
55. Pecha, B., et al., *J Clin Invest* 1989; 83:2102-2108.
- 5 56. Raleigh, E.A., et al., *Nucl Acid Res* 1988; 16:1563-75.
57. Ratnam, S., et al., *J Clin Microbiol* 1988; 26:2006-2012.
58. Riley, L.W., et al., *Infect Immun* 1987; 55:2052-2056.
59. Ritchie M., et al., *J Clin Microbiol* 1992; 30:461-464.
60. Rowe, P.C., et al., *Epidemiol Infect* 1993; 110:9-16.
- 10 61. Runnels, P.L., et al., *Infect Immun* 55:555-558, 1987.
62. Samadpour M., et al., *Appl Environ Microbiol* 1994; in press.
63. Sancar, A., et al., *J Bacteriol* 1979; 137:692-693.
64. Sherman, P., et al., *Infect Immun* 1991; 59:890-899.
65. Sherman, P.M., et al., *J Med Microbiol* 1988; 26:11-17.
- 15 66. Sherman, P., et al., *Infect Immun* 1988; 56:756-761.
67. Smith, D.B., et al., *Gene* 1988; 67:31-40.
68. Sojka, W.J., et al., *J Med Microbiol* 1978; 11:493-499.
69. Swerdlow, D.L., et al., *Ann Intern Med* 1992; 117:812-819.
70. Tarr, P.I., et al., *Am J Epidemiol* 1989; 129:582-586.
- 20 71. Tarr, P.I., et al., *J Infect Dis* 1989; 159:344-347.
72. Tarr, P.I., et al., *J Infect Dis* 1990; 162:553-556.
73. Taylor, R.K., et al., *J Bacteriol* 1989; 171:1870-1878.
74. Taylor, R.K., et al., *Proc Natl Acad Sci USA* 1987; 84:2833-2837.
75. Toth, I., et al., *Infect Immun* 1990; 58:1223-1231.
- 25 76. Wadolowski, E.A., et al., *Infect Immun* 1990; 58:2438-2445.
77. Wahl, G.M., et al., *Proc Natl Acad Sci USA* 1987; 84:2160-2164.
78. Wells, J.G., et al., *J Clin Micro* 1983; 18:512-520.
79. Wells, J.G., et al., *J Clin Microbiol* 1991; 29:985-989.
80. Wessels, M.R., et al., *Proc Natl Acad Sci USA* 1991; 88:8317-8321.
- 30 81. Yokoyama, H., et al., *Infect Immun* 1992; 60:998-1007.
82. Yu, J., et al., *Mol Microbiol* 1992; 6:411-7.

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

DNASIS  
a pEAR complete

Page 1

10 20 30 40 50  
 GGTACCTGTC GCCAGTTCTC CGATCTGTTT ACCCGGGAAA TTATCTCCTA  
 60 70 80 90 100  
 CAGCTTGTCA GAAAGGTCGG TGATGGAGCA TCGNTAATAC GATGCTATAC  
 110 120 130 140 150  
 GATGNATTCA CAGTGCCCGG CCAGAGGATG CCCCCGTCGCT GCATATGGAT  
 160 170 180 190 200  
 CAGNGTTGGC AATATCGAAT TGCAGGCTAT AGGCAAAGTT AANGCCCCAT  
 210 220 230 240 250  
 GGAGTAGCAC AAAATATGCC GCACANAGGA AACGGTCTGA ATAACGCAGT  
 260 270 280 290 300  
 GATGAAGAAC TTCTTCAGCA CACTGCTAAA ACGCATAGTG ATCGAGCGCT  
 310 320 330 340 350  
 GATTCTGGCG AACAACTGAA CTAATACATC AGAATCTGCA TTATGTTAAA  
 360 370 380 390 400  
 TAAATATAAA AAGATGGTTT AAATACCCCG TTACTTGTGA CTTACACTAT  
 410 420 430 440 450  
 ACGGTATCGC ATCGTTAAT ATTGCGACCG GCCAGATTTT TATTTCTATT  
 460 470 480 490 500  
 AGTTGTCACA ATACTGAATG CGTACGACCA CAGTATTCTG GCTCCTGTGT  
 510 520 530 540 550  
 GGTTATGCTT TAATTCTGCG TTCCGGGCAG ATAAGCAGTT GCTTCCAGGA  
 560 570 580 590 600  
 ATCCTTCTTG TGTTAATGTC AGTTCCCCCTT TTACCAAGTGC TGATTTCAC  
 610 620 630 640 650  
 ATTCCGTCCA ACAGAGCTTA TAGCCTTCC CTGGATTATA GCATTGTCCG  
 660 670 680 690 700  
 GCTGAAGTTC TTTTTGAATA ATAATAGAAG CACTGCTGGC AGATCCAGTC  
 710 720 730 740 750  
 CGTTTTTCAT AACCCACTGT ACTGATAACC ATAATCTAAT CAGTAGAAAT  
 760 770 780 790 800  
 TGAGTCGAAA ATAAGCACTA CTCCATACAG GATAATTAGA GGTCAGTTG  
 810 820 830 840 850  
 ATTATTCA CA ATTCACTCATC AGCATTCTCT ATTCTGACG AAATCAATAT  
 860 870 880 890 900  
 GAAAATAACC ATATATGATA ATTATTATAA TAACGGCTTT AATTGGAATA  
 910 920 930 940 950  
 CATATATTAC AACGTATTAT ATATAATTGG TATTCTGGGA ACTATATTCT  
 960 970 980 990 1000  
 CAAAATACAG TAGAAACGAG GTATGTTCT GGTGGAAAGG ACAGTGGGAT  
 1010 1020 1030 1040 1050  
 TAAAAAGTAA GAATTGATAA AAAAACGCCA GCAACACATA GTGCCGGNGG

DNASIS  
a pEAR complete

Page 2

1060 1070 1080 1090 1100  
 AGGGAAATACC CCATGGAGAA AATGTGATGC CTAGAGCATC ATGANTATAT  
  
 1110 1120 1130 1140 1150  
 AATTAAAAAT AGTTAGCGTT GTCACTACTT CNACAAAAT AATTTTCGTA  
  
 1160 1170 1180 1190 1200  
 GTATAGAAAG ATATTTTAT GCATGACCTA CCTGAATTG CTCCGGTAG  
  
 1210 1220 1230 1240 1250  
 AGGTTATAAA TAAAAATTGA ATCACGACAA ACACAATATT CATAGTATGG  
  
 1260 1270 1280 1290 1300  
 CGATGCCTAC GCCAGCAAGA ATAGCGNCAA TAATATTGGG AATATAATAG  
  
 1310 1320 1330 1340 1350  
 ACACCAGAGC CACAGGCATC TCACCTCTTA ACAAAACAACA ATCAGGATAT  
  
 1360 1370 1380 1390 1400  
 TTACTTTTAC CAAGCTAACT GTTACACCC AAAGTACACA CAATTAACCA  
  
 1410 1420 1430 1440 1450  
 TTCAATAACA AATGNCAATA TCCATAGCCA TACGACTTTA CCTTGTAAATG  
  
 1460 1470 1480 1490 1500  
 TTCGGTATTT CTTTATAATT ATTCTGGGAA ATCTAACATT TATTTTAAA  
  
 1510 1520 1530 1540 1550  
 ATCAAATTAT CTTGTTGTTT AAAAATAAGT TCACATACTT TATCATCTTC  
  
 1560 1570 1580 1590 1600  
 TTCCGCCATC AACATCTCTG CATACTTAAA CATTTCAGAA CGTTCTTTA  
  
 1610 1620 1630 1640 1650  
 GCACAGAAGA GTAATTATAT GTCCAGTTCC CAGGCAATAA TGCTTATGGA  
  
 1660 1670 1680 1690 1700  
 TATTTAAATTTC ATAATTTAGA GAATATTTG CAATAATATT TGGCAGTATT  
  
 1710 1720 1730 1740 1750  
 CAGAAATACC TGAAAATCA TACTATACAG CCCTAGGGAA TGGATAAAGA  
  
 1760 1770 1780 1790 1800  
 TTCTAACAAA GCATTTCAAC AATATATACT TGTTAAAAT CCATATCGAA  
  
 1810 1820 1830 1840 1850  
 ATGCCGTTGC AGCATTAAATA TATGCCTCAT TCATAAAATG TAAAAGAGCA  
  
 1860 1870 1880 1890 1900  
 AGCTCGTACC AGTAGGGGG AAATTCATTG ACATGCTCTG TCAATACGTA  
  
 1910 1920 1930 1940 1950  
 CAGAGCCCTG CCATGCTTGC CAGCACGTAA CAATTCCGCC CCCAGTAACC  
  
 1960 1970 1980 1990 2000  
 AGCGTGTTC CTGATTATTC TCAGGGTTAT ATGTTAGTAT TTTATCAATG  
  
 2010 2020 2030 2040 2050  
 AGTATAACGG CATCCTGATG ACGCTGTAAA TGAACATTG CCAGAATTGC  
  
 2060 2070 2080 2090 2100  
 AGCATAAAAGA GCGCAAATGC ATATGCCAGA TGAGCGTGAAT TATCAATGAT

DNASIS  
a pEAR complete

Page 3

2110 2120 2130 2140 2150  
 GTCAGGAGCA TGTCAGGCAA GACGCCCTGAG TTTGTTGACG TAATTTGTTT  
  
 2160 2170 2180 2190 2200  
 CGTTTATTTC ATCACTATCG TATGCCGTCAA GAGTTTTTC AAACTCATCC  
  
 2210 2220 2230 2240 2250  
 CGAAATGGGC CAAGCCTGGT TTCAAGGAAAT AAGAAATACC CTTGGTTATT  
  
 2260 2270 2280 2290 2300  
 GTTCACTTAA AAGTATAATT TGTAATTCAA ATCCTGAGCC TGTAAAGCGG  
  
 2310 2320 2330 2340 2350  
 GGAGTAACAT ATTCTATTCT GAAGAGAATA AAAGTCGTGA TGCAGATGTAT  
  
 2360 2370 2380 2390 2400  
 CAAGCCCGGA TTGTAATCCC AGATTAACAT AGATCACAAA ACAACTTATT  
  
 2410 2420 2430 2440 2450  
 CTTCACTAAC GTCAAGATAA ATATCGTTGT ATGCCCTTATC ACGACTACGA  
  
 2460 2470 2480 2490 2500  
 ATACCAGCAA GATACAAC TG ACATACGGAA AGATACCACG TTTTTTACTC  
  
 2510 2520 2530 2540 2550  
 CCGAAAATAA CGCTAAAAAG CTACTTCCCCC ATCGTTGTC CTTAGTATTG  
  
 2560 2570 2580 2590 2600  
 CCAGCGCCAA CAATGTGGC TGACATGATA AAGCTGTCTA GGAAATTGTT  
  
 2610 2620 2630 2640 2650  
 CGCCTCCTCA GCGGACAATC CAAATGGTGA TTGTCCTGT TAAACGTTA  
  
 2660 2670 2680 2690 2700  
 TTTTGAAGGT CGACTGAATA AGGTGATGAC GCTGTAGAAT TTTTACGTG  
  
 2710 2720 2730 2740 2750  
 CCACAGAATT TTGAACGCTT TCTCTTACAA TATTTCAATG TTTCTATCAG  
  
 2760 2770 2780 2790 2800  
 TATTGCGCCGG AAGAAGTCAT CGACCAAATC ATCCCAGTCG TCTCGCATCA  
  
 2810 2820 2830 2840 2850  
 CTGACCATTIC ATGGTTGACA TGTTGGAA ATCCGCTCT ACAGTAACCA  
  
 2860 2870 2880 2890 2900  
 TTTTTTATTTC GCAAACCGA ACACGCCATA CGGATAGCTG TTAACCTGGCA  
  
 2910 2920 2930 2940 2950  
 TGCCGAGGCA GTCGTTATT ATATTTGGTT TTGTCATAAA TCTTTATTTT  
  
 2960 2970 2980 2990 3000  
 TTGTAAAAGG CAAATATAAA TTATTCTCAT TATTGTTTGT ATTTGTGTAT  
  
 3010 3020 3030 3040 3050  
 TGTCTTGGCG GTTAACATGA TCGGAGATTA GTAATATCGG AATAACCACT  
  
 3060 3070 3080 3090 3100  
 CTGGCTTCCG TAGTCATTCC CTGTCTCGGA TTTTCAGCCA GCACCATAGC  
  
 3110 3120 3130 3140 3150  
 TGCTGCAGAG GATGTGATGA TTGTCTCGGC ATCCGGCTAT GAGAAAAAGC

(H) = SEQ ID NO: 11

(E) = SEQ ID NO: 9

(C) = SEQ ID NO: 4

DNASIS  
a pEAR complete

Page 4

3160	3170	3180	3190	3200
<u>TGACTAACGC AGCCGCCAGT GTTCTGTGA TTAGCCAGGA GGAATTGCAG</u>				
3210	3220	3230	3240	3250
<u>TCCAGCCAGT ACCACGATCT GGCGGAGGCT CTGAGATCAG TAGAGGGTGT</u>				
3260	3270	3280	3290	3300
<u>GGATGTTGAA AGTGGTACGG GTAAAACCGG AGGGCTGGAA ATCAGCATCC</u>				
3310	3320	3330	3340	3350
<u>GAGGAATGCC AGCCAGTTAC ACGCTGATAC TGATTGATGG TGTTCTCAG</u>				
3360	3370	3380	3390	3400
<u>GGCGGAAGCA GTGACGTGAC TCCCAACGGT TTTTCTGCCA TGAATACCGG</u>				
3410	3420	3430	3440	3450
<u>GTTCATGCC CCTCTGGCCG CCATTGAGCG TATTGAGGTT ATCAGGGGC</u>				
3460	3470	3480	3490	3500
<u>CGATGTCCAC ACTGTATGGC TCTGATGCGA TGGGCGGTGT GGTGAATATC</u>				
3510	3520	3530	3540	3550
<u>ATTACCAGAA AGAATGCAGA CAAATGGCTC TCTTCCGTCA ATGCAGGGCT</u>				
3560	3570	3580	3590	3600
<u>GAATCTGCAG GAAAGCAACA AATGGGGTAA CAGCAGCCAG TTTAATTTCT</u>				
3610	3620	3630	3640	3650
<u>GGAGCAGTGG TCCCCTTGTG GATGATTCTG TCAGCCTGCA GGTACGGCGT</u>				
3660	3670	3680	3690	3700
<u>AGCACACAAAC AGCGTCAGGG TTCATCGGTC ACATCACTGA GCGATACAGC</u>				
3710	3720	3730	3740	3750
<u>AGGCACCGGT ATTCCCTTATC CCACGGAGTC ACAGAATTAT AATCTTGGTG</u>				
3760	3770	3780	3790	3800
<u>CACGTCTTGA CTGGAAGGCG TCGGAGCAGG ATGTGCTCTG GTTTGATATG</u>				
3810	3820	3830	3840	3850
<u>E GATACCACCC GGCAGCGTTA TGATAACCGG GATGGGCAAC TGGGGAGTCT</u>				
3860	3870	3880	3890	3900
<u>GACGGGGGGGA TATGACCGGA CCCTGCGCTA TGAGCGAAC AAAATTTCAG</u>				
3910	3920	3930	3940	3950
<u>CTGGCTATGA TCATACTTTTC ACCTTCGGAA CATGGAAATC GTATCTGAAC</u>				
3960	3970	3980	3990	4000
<u>TGGAACGAGA CAGAAAATAA AGGTCGTGAG CTTGTACGCA GTGTACTGAA</u>				
4010	4020	4030	4040	4050
<u>GCGCGACAAA TGGGGGCTTG CCGGTCAGCC GCGGGAGCTT AAGGAATCGA</u>				
4060	4070	4080	4090	4100
<u>ACCTTATCCT GAATTCAATTA CTGCTTACCC CTCTGGGAGA ATCTCATCTG</u>				
4110	4120	4130	4140	4150
<u>GTTACGGTGG GGGGCGAGTT TCAGAGCTCG TCCATGAAAG ACGGAGTTGT</u>				
4160	4170	4180	4190	4200
<u>CCTTGCCAGC ACAGGTGAAA CTTTCCGGCA GAAAAGCTGG TCGGTATTTG</u>				

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

D

DNASIS  
a pEAR complete

4210	4220	4230	4240	4250
<u>CTGAGGATGA GTGGCATCTC ACGGATGCAC TTGCGCTGAC TCGGGGCAGC</u>				
4260	4270	4280	4290	4300
<u>CGCTATGAAC ATCATGAGCA ATTGGGGGGA CACTTCAGTC CGCGTGCATA</u>				
4310	4320	4330	4340	4350
<u>TCTGGTCTGG GATGTGGCAG ATGCCTGGAC GCTGAAAGGC GGTGTGACCA</u>				
4360	4370	4380	4390	4400
<u>CGGGATATAA GGCACCCAGA ATGGGGCAGC TACATAAAGG GATTAGTGGT</u>				
4410	4420	4430	4440	4450
<u>GTGTCGGGC AGGGAAAAAC AAATCTACTT GGTAACCCCG ACCTGAAGCC</u>				
4460	4470	4480	4490	4500
<u>GGAAGAGAGC GTCAGTTATG AGGCTGGGT GTATTACGAT AACCCCGCCG</u>				
4510	4520	4530	4540	4550
<u>GTCTGAATGC CAATGTCACA GGTTTTATGA CTGACTTCTC CAACAAGATT</u>				
4560	4570	4580	4590	4600
<u>GTCTCTTATT CCATAAATGA TAACACCAAT AGCTATGTAA ACAGCGAAA</u>				
4610	4620	4630	4640	4650
<u>GGCCCGGTTG CACGGTGTGG AATTTGCCGG CACATTGCCG CTGTGGTCAG</u>				
4660	4670	4680	4690	4700
<u>AGGATGTCAC GCTGTCACTG AATTACACCT GGACCCGAAG TGAACAACGT</u>				
4710	4720	4730	4740	4750
<u>GATGGTGATA ACAAAAGGTGC GCCGCTGAGT TATAACCCCTG AACACATGGT</u>				
4760	4770	4780	4790	4800
<u>GAATGCGAAA CTGAACTGGC AGATCACCGA AGAGGTGGCA TCATGGCTGG</u>				
4810	4820	4830	4840	4850
<u>GTGCCGTGTA TCGCGGGAAA ACACCACGTT TCACCCAGAA TTATTCGTCA</u>				
4860	4870	4880	4890	4900
<u>CTGAGCGCTG TACAGAAGAA AGTGTATGAT GAGAAAGGAG AATACCTGAA</u>				
4910	4920	4930	4940	4950
<u>AGCCTGGACG GTGGTGGATG CAGGTCTGTC GTGGAAGATG ACGGATGCC</u>				
4960	4970	4980	4990	5000
<u>TGACGCTGAA TGCTGCGGTG AATAACCTGC TCAACAAGGA TTACAGTGAC</u>				
5010	5020	5030	5040	5050
<u>GTGAGCCTGT ACAGTGCCGG TAAGAGTACG CTGTATGCCG GTGATTACTT</u>				
5060	5070	5080	5090	5100
<u>CCAGACGGGA TCATCAACAA CAGGATATGT GATACTGAG CGAAATTACT</u>				
5110	5120	5130	5140	5150
<u>GGATGTCGCT GAACTATCAG TTCTGATAAT AACAAAAAGGC TATCACTGAC</u>				
5160	5170	5180	5190	5200
<u>GTTGCCACTG CAACTCCTGG CGGAAACAGTG GCAACGTNTT</u>				
5210	5220	5230	5240	5250
<u>AGGTTAAGTG CATTTCGGAT CCGCTAATGA GATTTCGTTA CCAACAAC</u>				

G = SEQ ID NO: 10

I = SEQ ID NO: 12

DNASIS  
a pEAR complete

Page 6

5260 5270 5280 5290 5300  
 ATATCGTCAC AGGAAATGCA CGGATTATTT TTAACCTTATC ATTTACATAC

 5310 5320 5330 5340 5350  
 TTGTCCAGAG TGTNAGCGCA CCGCGACGGA CGTGGGGTAA AAATTAGTTT

 5360 5370 5380 5390 5400  
 ACAGAGAGAG TGACGTTCCA GGGGAACAAC TCTTTCATGC GGTTGGCAGG

 5410 5420 5430 5440 5450  
 CCAGGTGTTG GTTACACTGA TCACGTGGC GTTGGCCACG TTTCCGGNTC

 5460 5470 5480 5490 5500  
 GATTCCGTTA AGTTTGGAG CTACCGATCA GGCTGTACAT CACTGNCGCA

 5510 5520 5530 5540 5550  
 CTATCGCTCG TCATCTAAA GTCCGTCTC GTCAGCAGGA AGGTATCATT

 5560 5570 5580 5590 5600  
 CTCTCCCGCC ATTTTCCAG GGGNCCGGTC AGATAAGTCC CTTTGTCTAT

 5610 5620 5630 5640 5650  
 CGCTGACTCC TGACTCATAA CCCGGTTAGC AGAATGCAGG NTCACCACTC

 5660 5670 5680 5690 5700  
 GCCACGACCA AATCCAAATA AGTCAATTGC ACCTTCTCAA TCGCCATTTC

 5710 5720 5730 5740 5750  
 GTCAGTAAGC GTACAGCCTC AACTGATGGT ATCTTCACCA TCAATGACAA

 5760 5770 5780 5790 5800  
 CGGTGATCGC AATTTACTG ACGTTCGCCG GAACACGATC CAGTGCTATC

 5810 5820 5830 5840 5850  
 TCAATGCTGG CCTGCTGCGA ACCGGTAACG AGCCTGACTG CCCCCCTCAGG

 5860 5870 5880 5890 5900  
 AGAAGACAAA TTATTATAAA AGATAAAAGTC AGAATGCCA CTGACCTTTC

 5910 5920 5930 5940 5950  
 CCTGAGCATT AAGCATGAAC AGGGAGGTAT CGGGTTCGCC TTAAAAGCCG

 5960 5970 5980 5990 6000  
 GATTTGNACAG GGTACTGAAG ATTCAAGCCTG ATCGNAGATT GCTGAAGGGG

 6010 6020 6030 6040 6050  
 TATGTATTGT CCGGATTGTA AATTCAATATT AACTCTCCTG ATTTNTGATT

 6060 6070 6080 6090 6100  
 ATTATTAATG CGCAGCGTTT ATATATGTTC CCTAGGCTTA GTTCTGGACG

 6110 6120 6130 6140 6150  
 CTGGATATTC GGTGAGGCCTT AAATATGGTA TGACACCATT TTTCATAACG

 6160 6170 6180 6190 6200  
 CTGAAGTTTC TATACCTGTT GAATTTGAAT TTTCATTGAC CGGGTATCTT

 6210 6220 6230 6240 6250  
 ATTTTCCAGG GCCCGTTCCCT TCATAAGTCG CAAAAGTAAC ATATATCCGA

 6260 6270 6280 6290 6300  
 AGGGCATGCT GTTGATATCA GACACGGAAT ACTGGCTTAA ACCAGCAACC

DNASIS  
a pEAR complete

6310 6320 6330 6340 6350  
 ACAGATAAAC CGGGGGCTG CATAAAAGGT TCATGCCAGA ATTAACATAG  
 6360 6370 6380 6390 6400  
 CTCTGCTTTC TGCCCCCCCC TTTCCCATAT TCACCCGTTG ATAGCGGATC  
 6410 6420 6430 6440 6450  
 GATACCCAAA AAAAACCCCG GCATTGCCGG GGTCAGACTC AGCGTCTTTC *end of A*  
 6460 6470 6480 6490 6500  
 AGACATTGAC GCCGTGCTGG GAAGCAAGCG CTGACAGACC ACCGGCAAAA  
 6510 6520 6530 6540 6550  
 CNCTGGCCAA CAGCTTTAAA CTTCCACTCA GTACCATGGC GATACAGTTTC  
 6560 6570 6580 6590 6600  
 ACCGAAGACC ATTGCGGTTT CGGTTGAGGC GTCTTCAGAC AGATCGAAC  
 6610 6620 6630 6640 6650  
 GGGCAATTTC CGTCCCCTTG TCGTTGTTGT AAACGCGCAT GAAGCTGTTG  
 6660 6670 6680 6690 6700  
 CTCACCATGC CGAAGTTTTG TTTACGCGCT TCTGCATCAT AGATGGTAAC  
 6710 6720 6730 6740 6750  
 GGCAAATACC AGTTTTTGAGA TGTCTGCTGA GACTTTGGTC AGATCGATTTC  
 6760 6770 6780 6790 6800  
 TGACCTGCTC ATCGTCGCCG TCGCCTTCAC CGGTACGGTT GTCGCCCTGG  
 6810 6820 6830 6840 6850  
 TGCTCTACTG CGCCATCAGG GCTGGTTTTA TTATTGAAGA AAATGAAATG  
 6860 6870 6880 6890 6900  
 GGCATCTGAC AGTACTTTAC CGTCTTCACC TACTGCGAAT ACCGAAGCGT  
 6910 6920 6930 6940 6950  
 CCAGANCAA ACCCTGACCA TCGGTTACAC GGGCATCCC GCCCAGGCCA  
 6960 6970 6980 6990 7000  
 ACCATAGCGA CATTGATGGT TGGTGCTTCT TTGGTCAGAG ATACGTTGCC  
 7010 7020 7030 7040 7050  
 GCCTTTTACG AGAGAAACTG CCATTTTAG CTCTGCAAA CAGNTGAATG *A*  
 7060 7070 7080 7090 7100  
 AGGCTGAATA ACACCCCCAG AAATGAAAAG TTACTTTTCG ATCAGGACGC  
 7110 7120 7130 7140 7150  
 GTTAATNCCG TACTGAGCAC ATACAGATGC CAGACCACCA GCATAACNCT  
 7160 7170 7180 7190 7200  
 GTNCTACTGC GCGGAATTTC CACTCACCAT TGTGGCGAGA CAGCTCGCCG  
 7210 7220 7230 7240 7250  
 CGCAGCATGG CAGTCTCACT GGACGCATCT TCGGTCAGAT CGTAGCGAGC  
 7260 7270 7280 7290 7300  
 GACTTCAGTC TGGTTATCGT CATTAACCAG ACGAATAAAC GCACCGGATA  
 7310 7320 7330 7340 7350  
 CCTGACCACA GCTCTGGCGA CGAGCCTGAG CATCGTGGAT GGTACACAACG

A0:2

B

=

A

*end of B*

DNASIS  
a pEAR complete

Page 8

7360	7370	7380	7390	7400
AAGATGATCT TGTCAACTTC AGACGGGACG GCGTCCAGTT TAATTTTCAG				
7410	7420	7430	7440	7450
CGATTGATCA TCACCATCGC CCTCACCGGT GCGGTTATCG CCGGTGTGCG				
7460	7470	7480	7490	7500
TTACGGAACC GTCGGATGAC GTCAGGTTGT TATAGAAGAT GAAATCTGAA				
7510	7520	7530	7540	7550
TCGCCGCGCA CTTTGCCGTT TGAGGCCAGC AGGAATGCTG AAGCATCCAG				
7560	7570	7580	7590	7600
GTCAAAGTCC TGACCGTCTG TTGAACGCCG ATCCCAGCCA AGGCCACCA				
7610	7620	7630	7640	7650
GGACATTTTT CATTGACGGA CCTGCTTTAC TCAGGGAGAC GTTCCCGCCT				
7660	7670	7680	7690	7700
GTGGAAAGAG AAACACTCAT AAAATACCCCT CTTCGATTAG TAATTGTTCA				
7710	7720	7730	7740	7750
GGTTAACACT TAAGGGGATT ATCTCCCCCTT TTCCTCAGAT TCAGGTGTGC				
7760	7770	7780	7790	7800
CCGGGAACAT GACGCTTGCG AGAATGCCCA GCGCCAGTAC ACCCAGTACA				
7810	7820	7830	7840	7850
ACATACAGGC TGGTTGTTGC CGCGATGCTG TAACCATGAT GCCAGATGTG				
7860	7870	7880	7890	7900
ATCGATCGCA TTCAGGCCGA GTTTGCCAC GATGAAGAAC AGCANCACGA				
7910	7920	7930	7940	7950
TAGCGGCCTT CTCCAGATGN ACCAGGTNCT GTTTCAGTGC CTCNAGGACA				
7960	7970	7980	7990	8000
AAATACAGAG TACGCAGACC CAGGATAGCA AACATCATGG CACTATAGAC				
8010	8020	8030	8040	8050
GATGAAGCGG TTCACGACTG ACGGCAATGA TTTCCGGTAC C.....				

3  
A  
H  
S  
C  
B

END OF SEQ ID NO: 1

Page 9

SEQ NO: 5.

E.coli O157:H7 adhesin sequence>> 1 MRITTLASVVIP///CLGFSASSI 63  
Homology (if any)>> : : : :::  
IrgA amino acid sequence [V.cholera]>> MSRFNPNPSPVSLSVTLLGMLFSAS//

SEQ NO. 6

54 AAAED /////VMIVSASGYEKLTNAAASVSVISQEEQSSQYHDLAEALRSVEGVDVE 225  
: . :  
AFAQDATKTDETMVVTAAAGYAQVIQNAPASISVISREDLESRYRDVTDALKSVPGVTV/

406 IRGPMSLYGSDAMGGVVNIITRKNADKWLSVNAQLNLQESNKWGNSSQFNFWSSGPLV 585  
:::.....:::.....::: .. .: .. .: .. .: .. .: .. .: .. .: .. .: .. .:  
IRGPMSLYGSDAIGGVINIITRKDOQQWSGNVOLSTVVOENRASGDEOSANFFVTGPLS

760 DMDTTRQRYDNRDGQLGSLTGGYDRTLRYERNKISAGYDGTFTFGTWKSYLNWNETENKG 939  
VGKSAQSSGC /////RGTCNSNTDNOYRRNHVAVSHOGDWOGV/GOSDTYLOYEENTNKS

1117 LASTGETFRQKSWSVFAEDEWHLTDALALTAGSRYEHHEQFGGHFSPRAYLVWDVADA 1290  
.....  
KISSRTHISNTOWAGFIEDEWALAEFRLLTEGGRLDHDKNYGSHEPRVYGVNL.DPI.

1465 GLNANVTGFMTDFSNKI//VSYSINDNTNSYVNSGKA///RLHGVEFAG////TLPL 1608  
:: : . :  
GLAASLTAFHNDEKDKITRVA<sup>C</sup>PANICTAGPNOWGATPTYRVNIDEAFTYGA<sup>C</sup>ATLISI.

Page 10

1780 GKTPRFTQNYSSLAVQKKVYDEKGEYLKAWTVVDAGLSWKMTDALTLNAAVNNLLNK 1953  
:: : : : .  
GK///EMQPEGGASNDDFIAP////////SYTFIDTGVTYALTDATIKAAYVNLFDO

1954 DYSDVSLYSAGKSTLYAGDYFQTGSSTTGYVIPERNYWMSLNYQF\* 2091 END OF SEQ NO:5  
                  :::  :::  :::  :::  :::  :::  :::  :::  :::  :::  :::  :::  :::  :::  :::  
E//////////VNYAEY//////////GYVEDGRRYWLGLDIAF\* END OF SEQ NO:6

Slashes (/) indicate areas where gaps were inserted into the amino acid sequence to give the best possible alignment

" :" indicates an identical amino acid  
". " indicates a conserved amino acid



Page 12

1831 KKVYDEKGEYLKAWTVDAGLSWKMTDALTLNAAVNNILNKDYSVSLYSAGKSTI.YA 2004

KRADSATAKTPGGYTIWNTGAAWQVTKDVKLRAGVNLGDK//TANGTL

2005 GDYFQTGSSTTGYVI PERNYWM SLN YOF\* 2091 END OF SEQ ID NO: 7

• • • . . . . . . . .

DWKPDLSRDDYSYNEDGRRYFMAVDYRF END OF SEQ ID NO:8

Slashes (/) indicate areas where gaps were inserted into the amino acid sequence to give the best possible alignment

" :" indicates an identical amino acid

"." indicates a conserved amino acid

DNASIS  
Untitled1

Page 13

10 20 30 40 50 60  
ATGGAAGCAG CAAATTTAAG TCCTTCTGGT GCAGTAATGC CGCTGGCGAC CTCACTCAGT

70 80 90 100 110 120  
GGAAATAACT CAGTGGATGA GAAGACAGGA GTGATTAAC CAGAAAATGG AACAAATCGC

130 140 150 160 170 180  
ACCGTTAGAG TTATAGCCGG ATTAGCACTT ACCACTACGG CTCTGGCAGC TCTAGGTACA

190 200 210 220 230 240  
GGTATTGCAG CGGCATGCTC GGAGACGAGC AGCACAGAAAT ACTTAGCCCT GGGTATTACT

250 260 270 280 290 300  
TCTGGCGTAC TAGGTACTCT TACTGCCGTT GGCGGTGCAT TAGCGATGAA ATATGCCTAA

310 320 330 340 350 360  
.....